Lean Q Y, Shamsuddin N, Wan Ahmad W A
Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Med J Malaysia. 2008 Aug;63(3):216-21.
There are well-established guidelines regarding the use of Angiotensin converting enzyme inhibitors (ACEI) in the management of heart failure (HF). In-spite of that, many studies has documented underutilization of ACEI. Thus, this retrospective observational study aimed to evaluate the utilization of ACEI, to identify the pattern of ACEI use and the factors that might contribute to underutilization of ACEI. The target population was hospitalized HF patients in University Malaya Medical Centre (UMMC). Of 321 hospitalized HF patients, only 57% of them were treated with ACEI. 51.2% of the patients treated with ACEI received low dose (< or = 25% from target dose) at discharge. Factors that have significant association with the underutilization of ACEI included serum potassium and creatinine, chronic renal failure and other concurrent medications used (frusemide, aspirin, potassium chloride, calcium channel blockers and angiotensin receptor blockers). The findings indicated that the utilization of ACEI in the management of HF in UMMC is considerably low.
关于血管紧张素转换酶抑制剂(ACEI)在心力衰竭(HF)管理中的使用,已有完善的指南。尽管如此,许多研究已记录了ACEI使用不足的情况。因此,这项回顾性观察研究旨在评估ACEI的使用情况,确定ACEI的使用模式以及可能导致ACEI使用不足的因素。目标人群是马来亚大学医学中心(UMMC)的住院HF患者。在321名住院HF患者中,只有57%接受了ACEI治疗。在接受ACEI治疗的患者中,51.2%在出院时接受低剂量(<或=目标剂量的25%)治疗。与ACEI使用不足有显著关联的因素包括血钾和血肌酐、慢性肾衰竭以及使用的其他并发药物(速尿、阿司匹林、氯化钾、钙通道阻滞剂和血管紧张素受体阻滞剂)。研究结果表明,UMMC中ACEI在HF管理中的使用率相当低。